Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Uncontrolled Diabetes Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

NCT04919499
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 765128, Sham comparator
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Bakersfield, California • Sacramento, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

SPYRAL GEMINI Pilot Study

NCT06907147
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions
Multi-Organ Denervation Gemini System
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Stanford, California • Orlando, Florida • Safety Harbor, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 3 Interventional

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 20, 2026, 6:15 PM EDT
Not listed Phase 2 Interventional

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

NCT03279263
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MLR-1023, Placebo
Drug · Other
Lead sponsor
Melior Pharmaceuticals
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 4 Interventional

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

NCT05772169
View directory record Official record
Conditions
Hypercortisolism, Diabetes Mellitus, Type 2
Interventions
Mifepristone 300 MG [Korlym], Placebo for mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
36
States / cities
Escondido, California • Gardena, California • Huntington Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00327015
View directory record Official record
Conditions
Diabetes
Interventions
Saxagliptin, Metformin, Placebo, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
47
States / cities
Concord, California • Encinitas, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes.

NCT06926855
View directory record Official record
Conditions
Uncontrolled Diabetes, Uncontrolled Hypertension
Interventions
CHC-level cluster randomized control trial
Other
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years and older
Enrollment
72,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting No phase listed Observational

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT05692388
View directory record Official record
Conditions
Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
Interventions
Patient and Community Stakeholder Interviews, Cross-sectional Study Participants, Focus Groups and Intervention Mapping
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Feasibility and Impact of "ABCs of Diabetes" Self-Management Education Program at an Urban Public Library

NCT00822471
View directory record Official record
Conditions
Diabetes, Cardiovascular Disease
Interventions
Diabetes Self-Management Education
Behavioral
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 20, 2026, 6:15 PM EDT
Terminated Phase 4 Interventional

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

NCT02189395
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH and regular insulin, glargine and humalog
Drug
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Balance Control and Recovery in Diabetes Peripheral Neuropathy

NCT06544876
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathy Type 2, Diabetic Peripheral Neuropathy Type 2 - Uncontrolled, Healthy Aging
Interventions
sit-to-stand, stand to sit, standing perturbation, MRI of sciatic nerve
Behavioral · Other
Lead sponsor
Lisa Griffin
Other
Eligibility
50 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional

Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes

NCT05912647
View directory record Official record
Conditions
Diabetes, Diabetes Type 2
Interventions
MTM, CHW
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

NCT00357370
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting No phase listed Observational

Continuous Glucose Monitoring, Diabetes Education, and Peer Support for Management of Uncontrolled Type 2 Diabetes

NCT07054125
View directory record Official record
Conditions
Type 2 Diabetes Mellitus - Poor Control
Interventions
Education, lifestyle counseling, and peer support
Behavioral
Lead sponsor
Whole Endo
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Not applicable Interventional Results available

A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes

NCT03224234
View directory record Official record
Conditions
Diabetes
Interventions
Insulclock with feedback, Insulclock without feedback
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of a Smart-phone Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Non-insulin Dependent Diabetes Among Veterans

NCT05789706
View directory record Official record
Conditions
Diabetes, Diabete Type 2
Interventions
Dayamed Arthur a novel intelligent medication adherence platform
Behavioral
Lead sponsor
VA Sierra Nevada Health Care System
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Not applicable Interventional Results available

Piloting the IPROACTIF Program to Preserve Functioning and Prevent Cognitive Decline

NCT04682977
View directory record Official record
Conditions
Heart Disease (Coronary Artery Disease, Ischemic Heart Disease, Hypertensive Heart Disease), Uncontrolled Diabetes (HBA1c ≥ 10)
Interventions
IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning), Usual primary care services
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

NCT00396227
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, thiazolidinedione (TZD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,665 participants
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 4 Interventional Results available

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

NCT01512979
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
metformin, linagliptin, metformin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Chino, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

NCT03324776
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Model Clinical Research LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Adult Subjects With Uncontrolled Type 2 Diabetes

NCT02317796
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
MLR-1023
Drug
Lead sponsor
Melior Pharmaceuticals
Other
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
USA and South Korea, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 20, 2026, 6:15 PM EDT